Download the app
App StorePlay Store
Beige
Login
← All tags

diabetes

Ultra processed foods raise heart disease and death risk study finds alarming new link

Ultra processed foods raise heart disease and death risk study finds alarming new link

A new European cardiology report warns that people with the highest ultra processed food intake face notably greater risks of heart disease, irregular heart rhythms, obesity, diabetes, and cardiovascular death. The authors urge clinicians to more actively counsel patients on cutting back, saying the cumulative evidence points to ultra processed diets as a meaningful, modifiable health threat.

Summarised by Beize from a story on Republic on 12 May 2026
Dr Reddy’s and Nestle launch Celevida GLP+ for diabetes and obesity patients

Dr Reddy’s and Nestle launch Celevida GLP+ for diabetes and obesity patients

Dr Reddy’s has joined forces with Nestle Health Science to roll out Celevida GLP+, a nutrition supplement designed for people managing type 2 diabetes and obesity while on GLP-1/GIP therapy. The collaboration aims to address day to day nutritional challenges that can emerge during treatment, adding a targeted option beyond standard diabetes and weight management care.

Summarised by Beize from a story on The Economic Times on 7 May 2026

Your news, in seconds

App StorePlay Store
Novo Nordisk relaunches diabetes pills as Ozempic to win market share from Eli Lilly

Novo Nordisk relaunches diabetes pills as Ozempic to win market share from Eli Lilly

Novo Nordisk is relaunching a diabetes tablet in the United States under the Ozempic name, starting with select adult doses this Monday. The strategy banks on Ozempic’s blockbuster brand recognition to lift sales and help Novo regain market share from rival Eli Lilly as competition intensifies in diabetes care.

Summarised by Beize from a story on The Economic Times on 1 May 2026
Dr Reddy’s wins Health Canada approval for generic semaglutide injection first in Canada

Dr Reddy’s wins Health Canada approval for generic semaglutide injection first in Canada

Dr Reddy’s Laboratories has received market authorization from Health Canada for its generic semaglutide injection, becoming the first company approved for the diabetes therapy in Canada. The Bengaluru-based pharma is now preparing a launch to expand access for patients who rely on the treatment, potentially easing pressure on medication availability and costs.

Summarised by Beize from a story on The Economic Times on 29 Apr 2026
Lupin launches generic dapagliflozin and metformin tablets in the US after FDA approval

Lupin launches generic dapagliflozin and metformin tablets in the US after FDA approval

Lupin has launched generic anti-diabetic tablets in the United States—dapagliflozin and metformin hydrochloride extended-release—after receiving FDA approval. The company says its product is bioequivalent to Xigduo XR, positioning the launch as a potential new option for diabetes patients seeking effective treatment in the US market.

Summarised by Beize from a story on The Economic Times on 24 Apr 2026
Cipla bets on inhaled insulin Afrezza to win diabetes patients from injections

Cipla bets on inhaled insulin Afrezza to win diabetes patients from injections

Cipla is moving forward with the sale of Afrezza, an insulin patients inhale from the mouth, aiming to offer a painless alternative to injectable insulin. The big question is whether this inhaled option can gain traction against entrenched global players and established injection-based routines in diabetes care.

Summarised by Beize from a story on The Economic Times on 24 Apr 2026

Never miss a story

App StorePlay Store
Retatrutide sparks weight loss and longevity buzz as trials show striking metabolic results

Retatrutide sparks weight loss and longevity buzz as trials show striking metabolic results

Retatrutide, an investigational weight-loss drug, is drawing global attention after early clinical results showed substantial weight reduction. What makes it stand out is its “triple-action” approach, targeting three hormone receptors involved in metabolism. Researchers are also exploring whether it could support broader longevity goals, potentially offering new options for obesity and related diabetes.

Summarised by Beize from a story on The Economic Times on 24 Apr 2026
Page 1

The full experience is on mobile.

Swipe through stories, personalise your feed, and save articles for later — all on the app.

Download on the App StoreGet it on Google Play